Table 2

Clinical data for patients whose voriconazole dosages were changed

PatientDemographic and clinical dataaInitial voriconazole trough(s) (μg/ml)Voriconazole dose adjustmentbReason(s)Subsequent voriconazole troughs (μg/ml)c
120 yrs old, W, F, cystic fibrosis<0.20From 200 mg BID to 300 mg BIDPathogenic molds recovered from BAL specimend0.63, 0.65, 1.24
272 yrs old, W, M, idiopathic pulmonary fibrosis1.13From 200 mg BID to 200 mg dailyDrug intolerance with vision problem and hallucination0.5, 0.6, 0.76, 0.87
353 yrs old, W, F, COPD2.31, 1.93From 200 mg BID to 200 mg dailyNausea, vomiting<0.2 (twice)
442 yrs old, W, F, pulmonary fibrosis3.72, 4.11From 200 mg BID to 200 mg dailyNausea, vomiting(No follow-up levels)
563 yrs old, W, M, idiopathic pulmonary fibrosis4.8From 200 mg BID to 200 mg dailyHigh level of voriconazole0.87, 1.01, 1.18, 1.25, 1.42
670 yrs old, W, M, idiopathic pulmonary fibrosis4.93From 200 mg BID to 200 mg dailyHigh level of voriconazole1.94, 1.97, 2.16, 2.17
760 yrs old, W, M, COPD5.21From 200 mg BID to 200 mg dailyNausea, vomiting, and high level<0.2, 0.82
  • a The age, race (white [W]), gender (female [F] and male [M]), and underlying lung disease (chronic pulmonary obstructive disease [COPD]) are shown for each patient.

  • b The original dose is shown first and then the final dosage that each patient received until discharge from the hospital. BID, twice a day.

  • c The troughs are listed in increasing order.

  • d BAL, bronchoalveolar lavage.